NASDAQ$CARM
Carisma Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Carisma Therapeutics reported financial results for Q2 2024 and highlighted recent business updates.
Carisma Therapeutics reported that cash and cash equivalents are expected to fund the Company into the third quarter of 2025. Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024. Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025.
- Initial data for CT-0525, lead product candidate for anti-HER2 program, is expected by year-end 2024.
- A development candidate for the liver fibrosis program is expected to be nominated in the first quarter of 2025.
- The first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma was nominated under the Moderna Collaboration in the second quarter of 2024.
- Cash and cash equivalents of $40.4 million, along with $2.0 million received in July under the Moderna Collaboration, are expected to fund the Company into the third quarter of 2025.
Headline financials
Revenue & EPS history
Carisma Therapeutics · Revenue · Quarterly
$9.2M
Revenue by segment
Carisma Therapeutics · $19.6M total across 1 segment · Q4 2024
- Collaboration Revenues$19.6M—100.0%
Forward guidance
Carisma anticipates that its cash and cash equivalents of $40.4 million as of June 30, 2024 are sufficient to sustain its planned operations into the third quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q2 2024
+0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+6.2%
Avg return
30 days after
54%
26 / 48 earnings
Positive
+32.8%
Q2 2016
Best reaction
-29.2%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +6.2% | +10.1% | -98.0% | |
| Q3 2025 | +2.4% | +27.8% | +22.6% | |
| Q2 2025 | -11.8% | -8.6% | +31.7% | |
| Q1 2025 | +3.1% | -1.4% | +153.1% | |
| Q4 2024 | +11.5% | +5.7% | -5.6% | |
| Q3 2024 | -9.0% | -10.4% | -28.0% | |
| Q2 2024 | +10.7% | +26.2% | +25.0% | |
| Q1 2024 | -4.5% | -5.8% | -30.3% | |
| Q4 2023 | -11.5% | -19.8% | -28.2% | |
| Q3 2023 | -19.5% | -11.1% | -15.4% | |
| Q2 2023 | +12.9% | +22.4% | -12.9% | |
| Q1 2023 | -12.3% | -17.7% | +4.1% | |
| Q4 2022 | +1.2% | -9.6% | +62.9% | |
| Q3 2022 | +0.5% | — | — | |
| Q2 2022 | -3.6% | — | — | |
| Q1 2022 | -1.3% | — | — | |
| Q4 2021 | -2.5% | — | — | |
| Q3 2021 | +3.4% | — | — | |
| Q2 2021 | -8.8% | — | — | |
| Q1 2021 | +5.4% | — | — | |
| Q4 2020 | +5.6% | — | — | |
| Q3 2020 | +3.9% | — | — | |
| Q2 2020 | +7.0% | — | — | |
| Q1 2020 | +1.6% | — | — | |
| Q4 2019 | -29.2% | — | — | |
| Q3 2019 | +0.9% | — | — | |
| Q2 2019 | +1.7% | — | — | |
| Q1 2019 | -2.9% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | -7.0% | — | — | |
| Q2 2018 | +2.1% | — | — | |
| Q1 2018 | +17.1% | — | — | |
| Q4 2017 | +19.0% | — | — | |
| Q3 2017 | +2.8% | — | — | |
| Q2 2017 | -12.4% | — | — | |
| Q1 2017 | -2.7% | — | — | |
| Q4 2016 | +13.7% | — | — | |
| Q3 2016 | -4.2% | — | — | |
| Q2 2016 | +32.8% | — | — | |
| Q1 2016 | +6.1% | — | — | |
| Q4 2015 | -8.6% | — | — | |
| Q3 2015 | -0.7% | — | — | |
| Q2 2015 | +15.2% | — | — | |
| Q1 2015 | +17.9% | — | — | |
| Q4 2014 | -2.4% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -3.9% | — | — | |
| Q1 2014 | +1.1% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro